# Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia

> **NCT00025038** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 100 (actual)

## Conditions studied

- Juvenile Myelomonocytic Leukemia

## Interventions

- **DRUG:** tipifarnib
- **DRUG:** isotretinoin
- **DRUG:** fludarabine phosphate
- **DRUG:** cytarabine
- **RADIATION:** radiation therapy
- **DRUG:** cyclophosphamide
- **BIOLOGICAL:** anti-thymocyte globulin
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** double-unit umbilical cord blood transplantation
- **PROCEDURE:** umbilical cord blood transplantation
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00025038
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2007-10
- **Final completion:** —
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2013-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00025038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00025038, "Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT00025038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*